« Back
Home /
Partner: Integrated BioTherapeutics |Hölzel Diagnostika

Integrated BioTherapeutics

Integrated BioTherapeutics- Therapeutics & Vaccines

Integrated BioTherapeutics specializes in vaccines and therapeutics against emerging infectious diseases. Located in Maryland, USA, our partner works closely with renowned American government agencies, including the National Institute of Allergy and Infectious Diseases (NIAID/NIH), the National Cancer Institute (NCI), and the United States Army Medical Research Institute for Infectious Diseases (USAMRIID).

Integrated BioTherapeutics develops various antiviral and antibacterial pipelines for better control of infectious diseases. Antiviral products include Pan-Filovirus and Pan-Ebola Antibodies, Alphavirus Antibodies, Hepatitis C Antibodies and Filovirus Vaccines. The antibacterial pipeline contains toxoid vaccine against S. aureus enterotoxin B (SEB), ISTAb against Bacillus anthracis and Clostridium difficile infections.

Integrated BioTherapeutics' most advanced vaccine program focuses on a toxoid vaccine for the prevention of invasive diseases caused by Staphylococcus aureus infection. The toxoid vaccine is engineered to disarm proteins while maintaining immunogenicity. The toxoids are available in three classes of mutants: alpha-hemolysin, two-component leukotoxins and superantigens. The final active ingredient consists of seven toxoids and covers 12-15 toxins. Furthermore, Integrated BioTherapeutics works on viral glycoprotein vaccines such as Ebola, Marburg and Zika.

The most advanced immunotherapy program is a pan-Ebola virus constellation consisting of two largely neutralizing antibodies. These antibodies have shown protection against all pathogenic Ebola viruses in non-human primates and ferrets and are ready for IND-compatible studies.

A growing part of research and development is focused on two technologies called ISTAb and InstaVax. InstaVax is a novel technology that targets a universal antigen at the surface of an invading pathogen and redirects the antibody response to the antigen towards the heterologous pathogen. ISTAb is a genetically engineered monoclonal anti-toxin antibody that carries a target domain to attach to the surface of bacteria while removing the toxin and bacteria at the infection site (see below).

Infection Site Targeted neutralizing anti-toxin Antibodies (ISTAb)

Cd-ISTAb is a combination of two effective antibodies, that neutralize toxin A (TcdA) and toxin B (TcdB) produced by C. difficile. For the treatment of C. difficile infections, the antibodies are targeted to the surface of bacteria. The specific targeting to the infection site is caused by special phage-derived cell wall targeting domains (CWT domains) that bind the desired types of bacteria.